Drilldown: Medicines
Medicines > classes 
:
[[:Category:Antihypertensives|Antihypertensive]] or
[[:Category:Statins|Statin]]
& duration:
24 hours
:
[[:Category:Antihypertensives|Antihypertensive]] or
[[:Category:Statins|Statin]]
& duration:
24 hours Use the filters below to narrow your results.
generic:
brand:
Altace (1) ·
Altoprev (ER), Mevacor (discontinued US); mostly generic (1) ·
Avapro (1) ·
Benicar (1) ·
Cardura, Cardura XL (1) ·
Cozaar (1) ·
Crestor, Ezallor (1) ·
Diovan; Entresto (in fixed-dose combination with sacubitril) (1) ·
Hytrin (US brand discontinued); mostly generic (1) ·
Lotensin (1) ·
Micardis (1) ·
Norvasc, Katerzia (1) ·
Pravachol (1) ·
Zestril, Prinivil, Qbrelis (1)
classes: (Click arrow to add another value)
mechanism:
None (4) ·
'"`UNIQ--vote-00000053-QINU`"' Also raises bradykinin, contributing to vasodilation and the characteristic dry cough. Renally cleared, unmetabolized; dose-adjust by eGFR'"`UNIQ--ref-00000054-QINU`"'. (1) ·
'"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1) ·
'"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) ·
'"`UNIQ--vote-000000F7-QINU`"' Minimal CYP3A4 dependence (CYP2C9 minor) reduces drug-drug interactions; transport in and out of hepatocytes is largely via OATP1B1, making SLCO1B1 PGx genotype the most clinically actionable marker for statin-associated myopathy'"`UNIQ--ref-000000F8-QINU`"'. (1) ·
'"`UNIQ--vote-000003D1-QINU`"' SLCO1B1 polymorphism affects exposure but is most clinically actionable for simvastatin'"`UNIQ--ref-000003D2-QINU`"'. (1) ·
'"`UNIQ--vote-000004C8-QINU`"' Largely hepatically cleared (~80% biliary); no active metabolite. Sacubitril-valsartan (Entresto) combines an ARB with neprilysin inhibition for HFrEF and was a notable advance over the ARB-alone trial (PARADIGM-HF, 2014)'"`UNIQ--ref-000004C9-QINU`"'. (1) ·
'"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1) ·
'"`UNIQ--vote-00000A1D-QINU`"' Like other ACE inhibitors, it raises bradykinin (driving the dry cough and rare angioedema). Renally cleared; dose-adjust in renal impairment'"`UNIQ--ref-00000A1E-QINU`"'. (1) ·
'"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000055-QINU`"', '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"', '"`UNIQ--vote-00000058-QINU`"' (1) ·
'"`UNIQ--vote-00000075-QINU`"', '"`UNIQ--vote-00000076-QINU`"', '"`UNIQ--vote-00000077-QINU`"' (1) ·
'"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"' (1) ·
'"`UNIQ--vote-000000F9-QINU`"', '"`UNIQ--vote-000000FA-QINU`"', '"`UNIQ--vote-000000FB-QINU`"' (1) ·
'"`UNIQ--vote-000003D3-QINU`"', '"`UNIQ--vote-000003D4-QINU`"' (1) ·
'"`UNIQ--vote-000004CA-QINU`"', '"`UNIQ--vote-000004CB-QINU`"', '"`UNIQ--vote-000004CC-QINU`"' (1) ·
'"`UNIQ--vote-0000056B-QINU`"' (1) ·
'"`UNIQ--vote-00000805-QINU`"', '"`UNIQ--vote-00000806-QINU`"' (1) ·
'"`UNIQ--vote-00000840-QINU`"', '"`UNIQ--vote-00000841-QINU`"' (1) ·
'"`UNIQ--vote-00000A1F-QINU`"', '"`UNIQ--vote-00000A20-QINU`"', '"`UNIQ--vote-00000A21-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-00000AEC-QINU`"', '"`UNIQ--vote-00000AED-QINU`"' (1) ·
'"`UNIQ--vote-00000C2E-QINU`"', '"`UNIQ--vote-00000C2F-QINU`"', '"`UNIQ--vote-00000C30-QINU`"', '"`UNIQ--vote-00000C31-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
starting dose:
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg (1) ·
10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions) (1) ·
150 mg PO once daily; titrate to 300 mg if needed (1) ·
2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d (1) ·
2.5-5 mg PO once daily; titrate to 10 mg/d (1) ·
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) ·
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) ·
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) ·
40 mg PO once daily; titrate to 80 mg (1) ·
5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion) (1) ·
50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) ·
80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID) (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
preparations:
1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) ·
1, 2, 5, 10 mg capsules and tablets (1) ·
1.25, 2.5, 5, 10 mg capsules (1) ·
10 mg, 20 mg, 40 mg, 80 mg tablets (1) ·
10, 20, 40 mg tablets; 20, 40, 60 mg ER tablets (1) ·
2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) ·
2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution (1) ·
20, 40, 80 mg tablets (1) ·
25 mg, 50 mg, 100 mg tablets (1) ·
40, 80, 160, 320 mg tablets; oral suspension (1) ·
5, 10, 20, 40 mg tablets (2) ·
5, 20, 40 mg tablets (1) ·
75, 150, 300 mg tablets (1)
fda max:
10 mg/d (1) ·
100 mg/d (1) ·
16 mg/d (IR); 8 mg/d (XL) (1) ·
20 mg/d (1) ·
20 mg/d (hypertension); 10 mg/d (other indications typical) (1) ·
300 mg/d (1) ·
320 mg/d (hypertension); 320 mg/d (HF) (1) ·
40 mg/d (1) ·
40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg) (1) ·
80 mg/d (4) ·
80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions) (1)
routes:
onset:
BP and symptomatic LUTS improvement within 1-2 weeks (2) ·
BP effect 1-2 hours; max at 6 hours (1) ·
BP effect 1-2 weeks; antihypertensive peak 3-6 weeks (1) ·
BP effect 1-2 weeks; max at 2-3 weeks (1) ·
BP effect 2 hours; max at 4-6 weeks (1) ·
BP effect within 1-2 weeks (2) ·
BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) ·
BP lowering within 1 hour; max at 6 hours (1) ·
BP lowering within 1 hour; max effect at 6 hours (1) ·
LDL lowering at 1 week, max by 4 weeks (1) ·
LDL lowering at 2 weeks, max by 4 weeks (2)
duration: (Click arrow to add another value)
halflife:
10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' (1) ·
11-15 hours'"`UNIQ--ref-00000842-QINU`"' (1) ·
2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) ·
30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) ·
~12 hours (effective); terminal half-life is biphasic'"`UNIQ--ref-00000059-QINU`"' (1) ·
~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) ·
~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) ·
~13-17 hours (ramiprilat, the active metabolite)'"`UNIQ--ref-00000C32-QINU`"' (1) ·
~19 hours'"`UNIQ--ref-000000FC-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1) ·
~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1) ·
~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) ·
~6 hours'"`UNIQ--ref-000004CD-QINU`"' (1)
bioavailability:
42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) ·
60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' (1) ·
64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) ·
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"' (1) ·
~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' (1) ·
~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"' (1) ·
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) ·
~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"' (1) ·
~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) ·
~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000004CF-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000844-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-0000005B-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000A24-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension'"`UNIQ--ref-00000C34-QINU`"' (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 14 results in range #1 to #14.